Activating mutations of Shp2, which drive oncogenic Ras signaling, are associated with human cancers and Noonan syndrome (NS) (Tartaglia et al, 2001; Xu et al, 2010; Zhang et al, 2015). Here, PTPN11 is linked to cancer.